Elicio TherapeuticsELTX +4.85%32 Pretax Margin % is % as of Mar. 2026. GuruFocus rates ELTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Elicio Therapeutics ranks worse than 105820% on this metric.
The historical rank and industry rank for Elicio Therapeutics's Pretax Margin % or its related term are showing as below:
ELTX's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.63 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Elicio Therapeutics Pretax Margin % Related Terms
Elicio Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Elicio Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELTX vs CNTN, NBP, NGEN: Pretax Margin % Comparison
For the Biotechnology subindustry, Elicio Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicio Therapeutics (ELTX) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Elicio Therapeutics and its competitors. According to the industry distribution chart, Elicio Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Elicio Therapeutics' Pretax Margin % too high?
Elicio Therapeutics' current Pretax Margin % is %. Based on the distribution chart, Elicio Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Elicio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Pretax Margin % compare to CNTN and NBP?
According to the Biotechnology industry distribution chart, Elicio Therapeutics ranks #999999 out of 945 companies for Pretax Margin %. This places Elicio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Pretax Margin % of %. The current Pretax Margin % is %. Elicio Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
32GF Score
Get the complete analysis for ELTX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTX has been successfully added to your 
